menu
    • menu
    [{"orgOrder":0,"company":"Replicate Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"RBI-4000","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Replicate Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Replicate Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Replicate Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Replicate Bioscience","sponsor":"Curia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"RBI-4000","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Replicate Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Replicate Bioscience \/ Curia","highestDevelopmentStatusID":"6","companyTruncated":"Replicate Bioscience \/ Curia"},{"orgOrder":0,"company":"Replicate Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"RBI-4000","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Replicate Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Replicate Bioscience \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Replicate Bioscience \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Replicate Bioscience

    Menu

    Replicate Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Replicate Bioscience

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Replicate Bioscience

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RBI-4000

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Replicate Bioscience Announces Positive Results for Next-Generation srRNA Technology

                            Details : RBI-4000 is a novel self-replicating RNA (srRNA) vaccine candidate, which stimulate virus-neutralizing immune responses to rabies. It is being developed for the treatment of rabies infection.

                            Brand Name : RBI-4000

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            February 14, 2024

                            Lead Product(s) : RBI-4000

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Replicate Bioscience

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Replicate Bioscience

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RBI-4000

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Curia

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Curia Supports Replicate Bioscience's Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

                            Details : RBI-4000, is a self-replicating (srRNA) rabies vaccine, which is investigated in a Phase 1 clinical study utilizing clinical material developed as part of the collaboration with Curia.

                            Brand Name : RBI-4000

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            September 13, 2023

                            Lead Product(s) : RBI-4000

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Curia

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Replicate Bioscience

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Replicate Bioscience

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RBI-4000

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation srRNA Vaccine

                            Details : RBI-4000, is an next generation srRNA technology vaccine developed to stimulate virus-neutralizing immune responses to rabies virus for prophylactic use.

                            Brand Name : RBI-4000

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            September 12, 2023

                            Lead Product(s) : RBI-4000

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth